Cargando…
Cefoperazone/sulbactam-induced hemolytic anemia
Drug-induced hemolytic anemia (DIHA) is a rare complication of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound prepared from the third generation of cephalosporin and β-lactamase inhibitor. There are limited data of DIHA induced from cefoperazone/sulbactam. A 93-year-ol...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997602/ https://www.ncbi.nlm.nih.gov/pubmed/34528516 http://dx.doi.org/10.4103/jpgm.JPGM_1335_20 |
_version_ | 1784903289560629248 |
---|---|
author | Sun, XM Liu, LH Wu, Q Wang, HG |
author_facet | Sun, XM Liu, LH Wu, Q Wang, HG |
author_sort | Sun, XM |
collection | PubMed |
description | Drug-induced hemolytic anemia (DIHA) is a rare complication of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound prepared from the third generation of cephalosporin and β-lactamase inhibitor. There are limited data of DIHA induced from cefoperazone/sulbactam. A 93-year-old female patient, who had an operation on the biliary tract 3 months ago, was admitted to our hospital with an abdominal infection. After cefoperazone/sulbactam was given as anti-infection treatment, the patient developed hemolytic anemia on the third day. Cefoperazone/sulbactam was discontinued and replaced with meropenem. Subsequently the level of red blood cells, hemoglobin, and hematocrit returned to normal. Clinicians should pay attention to monitoring the possible adverse reactions during the use of cefoperazone/sulbactam and should be aware of the occurrence of DIHA, so as to give timely treatment. |
format | Online Article Text |
id | pubmed-9997602 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-99976022023-03-10 Cefoperazone/sulbactam-induced hemolytic anemia Sun, XM Liu, LH Wu, Q Wang, HG J Postgrad Med ADR Report Drug-induced hemolytic anemia (DIHA) is a rare complication of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound prepared from the third generation of cephalosporin and β-lactamase inhibitor. There are limited data of DIHA induced from cefoperazone/sulbactam. A 93-year-old female patient, who had an operation on the biliary tract 3 months ago, was admitted to our hospital with an abdominal infection. After cefoperazone/sulbactam was given as anti-infection treatment, the patient developed hemolytic anemia on the third day. Cefoperazone/sulbactam was discontinued and replaced with meropenem. Subsequently the level of red blood cells, hemoglobin, and hematocrit returned to normal. Clinicians should pay attention to monitoring the possible adverse reactions during the use of cefoperazone/sulbactam and should be aware of the occurrence of DIHA, so as to give timely treatment. Wolters Kluwer - Medknow 2023 2021-09-13 /pmc/articles/PMC9997602/ /pubmed/34528516 http://dx.doi.org/10.4103/jpgm.JPGM_1335_20 Text en Copyright: © 2021 Journal of Postgraduate Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | ADR Report Sun, XM Liu, LH Wu, Q Wang, HG Cefoperazone/sulbactam-induced hemolytic anemia |
title | Cefoperazone/sulbactam-induced hemolytic anemia |
title_full | Cefoperazone/sulbactam-induced hemolytic anemia |
title_fullStr | Cefoperazone/sulbactam-induced hemolytic anemia |
title_full_unstemmed | Cefoperazone/sulbactam-induced hemolytic anemia |
title_short | Cefoperazone/sulbactam-induced hemolytic anemia |
title_sort | cefoperazone/sulbactam-induced hemolytic anemia |
topic | ADR Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997602/ https://www.ncbi.nlm.nih.gov/pubmed/34528516 http://dx.doi.org/10.4103/jpgm.JPGM_1335_20 |
work_keys_str_mv | AT sunxm cefoperazonesulbactaminducedhemolyticanemia AT liulh cefoperazonesulbactaminducedhemolyticanemia AT wuq cefoperazonesulbactaminducedhemolyticanemia AT wanghg cefoperazonesulbactaminducedhemolyticanemia |